AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • AdARRC™
    • About Us
    • Committee
    • Future Dates of AdARRC™
    • History
      • Previous Speakers of AdARRC™
      • AdARRC Academy™
      • AdARRC Summit™
    • Annual Initiatives
      • Best Image Competition
      • Nominate a Trainee Winner
  • Registration
    • Register Now
    • Venue & Accommodation
    • UAE Visa Application
  • Call for Abstracts
  • Best Image Competition
  • Nominate a Trainee
  • Scientific Agenda
  • Sponsorship
    • Sponosors
    • Become a Sponsor or Exhibitor
×

Author: AdARRC™

 Multiple steroid injections into arthritic joints do not improve outcomes more than other injections
AdARRC™ September 20, 2021 Monday Weekly Update

Multiple steroid injections into arthritic joints do not improve outcomes more than other injections

Question Are multiple intra-articular corticosteroid injections more effective and safer than other joint injections in patients with degenerative joint disease? Conclusion In this systematic review, patients with degenerative joint disease who received multiple corticosteroid injections did not have more meaningful…
Read More
 Type of shoe doesn’t seem to matter for moderate to severe knee osteoarthritis due to medial joint space narrowing
AdARRC™ September 13, 2021 Monday Weekly Update

Type of shoe doesn’t seem to matter for moderate to severe knee osteoarthritis due to medial joint space narrowing

Question Are flat flexible shoes as effective as stable supportive shoes to decrease pain in patients with knee osteoarthritis? Conclusion Tell patients with knee pain to experiment to see if changing their shoe type produces pain relief. In this study,…
Read More
 FDA Approved  Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus
AdARRC™ August 9, 2021 Monday Weekly Update

FDA Approved Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

The Drug The U.S. Food and Drug Administration (FDA) has approved Saphnelo™ (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. It is the third U.S. FDA approval of a lupus therapy since…
Read More
 Rapid antigen tests for COVID-19 are much less sensitive in asymptomatic persons (40% vs 80% in symptomatic persons)
AdARRC™ June 21, 2021 Monday Weekly Update

Rapid antigen tests for COVID-19 are much less sensitive in asymptomatic persons (40% vs 80% in symptomatic persons)

Question How accurate are rapid antigen tests for COVID-19 in both asymptomatic and symptomatic patients? Conclusion A rapid antigen test (Sofia FIA from Quidel) was highly specific, but sensitivity was 80% in symptomatic patients and only 40% in asymptomatic patients.…
Read More
 Epidural steroid injections provide minimal, if any, benefit in low back pain with sciatica
AdARRC™ June 14, 2021 Monday Weekly Update

Epidural steroid injections provide minimal, if any, benefit in low back pain with sciatica

Question For patients with sciatica, do epidural corticosteroid injections safely reduce pain and disability? Conclusion Epidural corticosteroid injections provide a small and probably clinically insignificant reduction in leg and back pain in the immediate term (< 2 weeks), and a…
Read More
 Ultrasound-guided steroid injections are more accurate than blind injections for frozen shoulder, but outcomes are similar
AdARRC™ June 7, 2021 Monday Weekly Update

Ultrasound-guided steroid injections are more accurate than blind injections for frozen shoulder, but outcomes are similar

Question Are ultrasound-guided intra-articular steroid injections more accurate than blind injections? Conclusion In this study from at a single center where steroid injections were given by a single experienced clinician, ultrasound (US)-guided intra-articular injections were more accurate than blind injection.…
Read More
 Convalescent plasma does not  improve outcomes in patients  hospitalized with severe COVID-19  pneumonia (PlasmAr)
AdARRC™ May 17, 2021 Monday Weekly Update

Convalescent plasma does not improve outcomes in patients hospitalized with severe COVID-19 pneumonia (PlasmAr)

Question Does convalescent plasma improve outcomes in patients hospitalized with severe pneumonia due to SARS-CoV-2? Conclusion In this study, convalescent plasma did not improve outcomes in patients hospitalized with severe COVID-19 pneumonia. Reference Simonovich VA, Burgos Pratx LD, Scibona P,…
Read More
 Tofacitinib Does Not Increase Risk of Venous Thromboembolism in Patients With RA
AdARRC™ May 10, 2021 Monday Weekly Update

Tofacitinib Does Not Increase Risk of Venous Thromboembolism in Patients With RA

Question Does Tofacitinib Increase the Risk of Venous Thromboembolism in Patients with RA? Conclusion Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in…
Read More
 Tocilizumab and sarilumab are effective for critically ill patients with COVID-19 who require organ support
AdARRC™ May 3, 2021 Monday Weekly Update

Tocilizumab and sarilumab are effective for critically ill patients with COVID-19 who require organ support

Question Are monoclonal antibodies against the interleukin-6 receptor effective in patients who are critically ill with COVID-19? Conclusion In patients who are critically ill with COVID-19 and require respiratory or cardiovascular organ support, the monocloncal antibodies tocilizumab and sarilumab reduce…
Read More
 Single-dose opioid analgesics  offer no benefit over non-narcotic  analgesia for musculoskeletal pain
AdARRC™ April 26, 2021 Monday Weekly Update

Single-dose opioid analgesics offer no benefit over non-narcotic analgesia for musculoskeletal pain

Question For acute muscle pain, what oral analgesic provides the best immediate relief? Conclusion A single dose of opioid analgesics provides similar acute pain relief to a single dose of a combination of acetaminophen and ibuprofen in patients with acute…
Read More
  • 1
  • …
  • 3
  • 4
  • 5
  • 6

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

Important Dates

Registration

  • Early Bird: 04 April 2025
  • Standard: 03 July 2025
  • Late/Onsite: 04 September 2025

Call for Abstracts

  • Submission Opens 16 April 2025
  • Submission Deadline: 15 July 2025
  • Acceptance Notification: 10 August 2025

 

Best Image

  • Submission Opens: 28 April 2025
  • Submission Deadline: 28 July 2025

© 2025 AdARRC™. All rights reserved